Naltrexone and Glecaprevir/Pibrentasvir Interaction

Understanding the Naltrexone and Glecaprevir/Pibrentasvir Interaction

FDA-approved prescribing information for these two drugs flags their combination as a minor-severity interaction. Naltrexone belongs to the Opioid Antagonist class and Glecaprevir/Pibrentasvir belongs to the NS3/4A/NS5A Inhibitor (HCV) class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: There is not enough research yet to know exactly how these two drugs affect each other in the body. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Naltrexone has 5 total documented interactions on file in this dataset, and Glecaprevir/Pibrentasvir has 38. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Talk to your doctor before taking these together because the safety of this combination is not yet known. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Naltrexone or Glecaprevir/Pibrentasvir based on a web page, speak with your prescriber or pharmacist before making any change.